MCID: HYP085
MIFTS: 47

Hypothalamic Disease

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hypothalamic Disease

MalaCards integrated aliases for Hypothalamic Disease:

Name: Hypothalamic Disease 12 15
Hypothalamic Dysfunction 76 53
Hypothalamic Diseases 44 73
Hypothalamic Dysfunction Syndromes 73
Hypothalamic Disorder 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1931
MeSH 44 D007027
SNOMED-CT 68 88108008
ICD10 33 E23.3

Summaries for Hypothalamic Disease

NIH Rare Diseases : 53 Hypothalamic dysfunction refers to a condition in which the hypothalamus is not working properly. The hypothalamus produces hormones that control body temperature, hunger, moods, release of hormones from many glands such as the pituitary gland, sex drive, sleep, and thirst. The signs and symptoms patients have vary depending on the hormones missing. A number of different causes including anorexia, bleeding, genetic disorder, tumors, and more have been linked to hypothalamic dysfunction. Treatment depends on the cause of the hypothalamic dysfunction.

MalaCards based summary : Hypothalamic Disease, also known as hypothalamic dysfunction, is related to mccune-albright syndrome and precocious puberty. An important gene associated with Hypothalamic Disease is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are G-Beta Gamma Signaling and Peptide ligand-binding receptors. The drugs Hydrocortisone and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and hypothalamus, and related phenotypes are endocrine/exocrine gland and immune system

Wikipedia : 76 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypothalamic Disease

Diseases related to Hypothalamic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 mccune-albright syndrome 29.6 GH1 PRL
2 precocious puberty 29.5 GH1 GNRH1
3 diabetes insipidus 29.5 CRH POMC PRL
4 amenorrhea 29.4 CRH GNRH1 POMC PRL
5 craniopharyngioma 29.3 GH1 GNRH1 PRL
6 major depressive disorder 29.3 CRH POMC PRL
7 hypothyroidism 29.2 GH1 POMC PRL
8 anorexia nervosa 29.1 CRH GH1 GHRH POMC PRL
9 prader-willi syndrome 29.0 GH1 GNRH1 POMC
10 conn's syndrome 28.9 CRH GH1 POMC PRL
11 hyperprolactinemia 28.9 GH1 GNRH1 POMC PRL
12 acromegaly 28.8 GH1 GHRH POMC PRL
13 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.5
14 rohhad 12.1
15 shapiro syndrome 11.2
16 fryns microphthalmia syndrome 11.1
17 froelich syndrome 10.9
18 hypothalamic adipsic hypernatraemia syndrome 10.4
19 melancholia 10.1 CRH PRL
20 spinocerebellar degeneration 10.1 CRH PRL
21 fibromyalgia 10.1 CRH PRL
22 postpartum depression 10.1 CRH PRL
23 hypogonadotropism 10.1 GNRH1 PRL
24 pelvic varices 10.1 GNRH1 PRL
25 fibrous dysplasia 10.1 GH1 PRL
26 fibrous dysplasia/mccune-albright syndrome 10.1 GH1 PRL
27 pseudohypoparathyroidism, type ia 10.1 GH1 PRL
28 anovulation 10.0 GNRH1 PRL
29 adenomyosis 10.0 GNRH1 PRL
30 endogenous depression 10.0 CRH GNRH1
31 tetrahydrobiopterin deficiency 10.0 GH1 PRL
32 pituitary adenoma 1, multiple types 10.0 GH1 PRL
33 varicocele 10.0 GNRH1 PRL
34 pituitary stalk interruption syndrome 10.0 GH1 PRL
35 isolated growth hormone deficiency, type ib 10.0 GH1 GHRH
36 isolated growth hormone deficiency 10.0 GH1 GHRH
37 growth hormone deficiency 10.0 GH1 GHRH
38 aromatase deficiency 10.0 GH1 GNRH1
39 isolated growth hormone deficiency, type ii 10.0 GH1 GHRH
40 gangliocytoma 10.0 CRH POMC
41 acth deficiency, isolated 10.0 CRH POMC
42 fasting hypoglycemia 10.0 CRH POMC
43 female reproductive system disease 10.0 GNRH1 PRL
44 adrenal cortical hypofunction 10.0 CRH POMC
45 withdrawal disorder 10.0 CRH POMC
46 reproductive system disease 10.0 GNRH1 PRL
47 ectopic cushing syndrome 10.0 CRH POMC
48 persistent fetal circulation syndrome 10.0 CRH POMC
49 dwarfism 10.0 GH1 GHRH
50 abducens nerve disease 10.0 POMC PRL

Graphical network of the top 20 diseases related to Hypothalamic Disease:



Diseases related to Hypothalamic Disease

Symptoms & Phenotypes for Hypothalamic Disease

MGI Mouse Phenotypes related to Hypothalamic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 CRH GHRH GNRH1 POMC PRL
2 immune system MP:0005387 9.35 CRH GHRH GNRH1 POMC PRL
3 liver/biliary system MP:0005370 9.02 CRH GHRH GNRH1 POMC PRL

Drugs & Therapeutics for Hypothalamic Disease

Drugs for Hypothalamic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-23-7 5754
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-03-3
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
7
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
8
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
9 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 383414 6400441
11
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
12
Mecasermin Approved, Investigational Phase 4,Phase 3,Not Applicable 68562-41-4
13
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
14
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
15
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 7440-66-6
16
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
18
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
19 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 979-32-8
20
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Morphine Approved, Investigational Phase 4 57-27-2 5288826
23
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
28
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
29
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
30
Cosyntropin Approved Phase 4 16960-16-0 16129617
31
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
32
Liraglutide Approved Phase 4 204656-20-2 44147092
33
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
34
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
35
Cefdinir Approved Phase 4 91832-40-5 6915944
36
leucovorin Approved Phase 4,Phase 1 58-05-9 6006 143
37
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
38
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
39
Cefazolin Approved Phase 4 25953-19-9 656510 33255
40
Sulfamethoxazole Approved Phase 4 723-46-6 5329
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
42
Prednisolone hemisuccinate Experimental Phase 4,Phase 2 2920-86-7
43
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Adrenergic alpha-Agonists Phase 4,Phase 3,Not Applicable
46 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Hydrocortisone-17-butyrate Phase 4,Not Applicable,Early Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Not Applicable
49 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 Hypnotics and Sedatives Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
4 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
5 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
6 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
7 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
8 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
9 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
10 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
11 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
12 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
13 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
14 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
15 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
16 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
17 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
18 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
19 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
20 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
21 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
22 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
23 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
24 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
25 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
26 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
27 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
28 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
29 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
30 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
31 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
32 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
33 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
34 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
35 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
36 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
37 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
38 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
39 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
40 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
41 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
42 Easypod United States User Trial Completed NCT00689260 Phase 4
43 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
44 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
45 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
46 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
47 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
48 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
49 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
50 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment

Search NIH Clinical Center for Hypothalamic Disease

Cochrane evidence based reviews: hypothalamic diseases

Genetic Tests for Hypothalamic Disease

Anatomical Context for Hypothalamic Disease

MalaCards organs/tissues related to Hypothalamic Disease:

41
Pituitary, Brain, Hypothalamus, Bone, Ovary, Thyroid, Cortex

Publications for Hypothalamic Disease

Articles related to Hypothalamic Disease:

(show top 50) (show all 132)
# Title Authors Year
1
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation associated with neuroblastoma. ( 29380520 )
2018
2
Perioperative anesthetic management of children with congenital central hypoventilation syndrome and rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation undergoing thoracoscopic phrenic nerve-diaphragm pacemaker implantation. ( 30251310 )
2018
3
Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications. ( 29052045 )
2018
4
Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment. ( 30377030 )
2018
5
Hypothalamic Dysfunction in Obesity and Metabolic Disorders. ( 28933062 )
2017
6
Case of Werner syndrome complicated by adrenal insufficiency due to hypothalamic dysfunction. ( 28240455 )
2017
7
Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. ( 28900724 )
2017
8
Psychiatric Symptoms in Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome and its Treatment: A Case Report. ( 26830999 )
2016
9
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome and celiac disease in a 13-year-old girl: further evidence for autoimmunity? ( 26352082 )
2016
10
Hypoventilation improvement in an adult non-invasively ventilated patient with Rapid-onset Obesity with Hypothalamic Dysfunction Hypoventilation and Autonomic Dysregulation (ROHHAD). ( 29543408 )
2016
11
Chordoid glioma: A new paradigm of hypothalamic dysfunction? ( 27798757 )
2016
12
Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation and neuroendocrine tumor syndrome with a homogenous enlargement of the pituitary gland: a case report. ( 27876089 )
2016
13
Bardoxolone methyl prevents obesity and hypothalamic dysfunction. ( 27417254 )
2016
14
Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation. ( 27662896 )
2016
15
Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation in Saudi Arabia. ( 27761566 )
2016
16
Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation syndrome. ( 26229761 )
2015
17
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): Response to ventilatory challenges. ( 25776886 )
2015
18
Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome. ( 25454350 )
2015
19
Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome May Have a Hypothalamus-Periaqueductal Gray Localization. ( 25746964 )
2015
20
Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours. ( 26302956 )
2015
21
Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction. ( 26113818 )
2015
22
Pituitary and/or hypothalamic dysfunction following moderate to severe traumatic brain injury: Current perspectives. ( 26693424 )
2015
23
Gut-Brain: Major Depressive Disorder, Hypothalamic Dysfunction, and High Calcium Score Associated With Leaky Gut. ( 26348609 )
2015
24
Severe phenotype of rapid-onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysfunction syndrome. ( 24492667 )
2014
25
Intrathecal synthesis of oligoclonal bands in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome: new evidence supporting immunological pathogenesis. ( 23292759 )
2014
26
Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. ( 24990930 )
2014
27
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: review and update. ( 24914877 )
2014
28
Hypothalamic Dysfunction of the Thrombospondin Receptor I+2I'-1 Underlies the Overeating and Obesity Triggered by Brain-Derived Neurotrophic Factor Deficiency. ( 24403154 )
2014
29
Hypothalamic Dysfunction Without Hamartomas Causing Gelastic Seizures in Optic Nerve Hypoplasia. ( 24700666 )
2014
30
Reversible hypothalamic dysfunction in optic nerve germinoma. ( 23524717 )
2013
31
A case of rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor: ROHHADNET syndrome. ( 23186956 )
2013
32
Commentary: Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): Remember Your ABCs (Airway, Breathing, Circulation). ( 23970914 )
2013
33
Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. ( 23318724 )
2013
34
Systemic effects of hypothermia due to hypothalamic dysfunction after resection of a craniopharyngioma: case report and review of literature. ( 23047234 )
2013
35
Nocturnal Anxiety in a Youth with Rapid-onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD). ( 23970913 )
2013
36
Anesthetic considerations for rapid-onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysfunction (ROHHAD) syndrome in children. ( 22862685 )
2013
37
Noninvasive ventilation in a child with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD). ( 23059524 )
2012
38
Hypothalamic dysfunction in a patient with primary lymphoma of the central nervous system. ( 21822693 )
2012
39
Bilateral paramedian thalamic infarction with hypothalamic dysfunction. ( 22773515 )
2012
40
Hypothalamic dysfunction in obesity. ( 22954151 )
2012
41
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): a case with additional features and review of the literature. ( 22715259 )
2011
42
Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome. ( 20727534 )
2011
43
Partial reversibility of hypothalamic dysfunction and changes in brain activity after body mass reduction in obese subjects. ( 21515852 )
2011
44
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: analysis of hypothalamic and autonomic candidate genes. ( 21691246 )
2011
45
Hypothalamic dysfunction in a female with isolated hypogonadotropic hypogonadism and compound heterozygous TACR3 mutations and clinical manifestation in her heterozygous mother. ( 20395662 )
2010
46
Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. ( 19946044 )
2010
47
A case of late-onset central hypoventilation syndrome with hypothalamic dysfunction: through a new phenotype. ( 20560260 )
2010
48
Postpartum hypothalamic dysfunction--a case report. ( 20806185 )
2010
49
Immunoglobulin therapy in idiopathic hypothalamic dysfunction. ( 19664546 )
2009
50
Hypothalamic dysfunction in obesity. ( 20397624 )
2009

Variations for Hypothalamic Disease

Expression for Hypothalamic Disease

Search GEO for disease gene expression data for Hypothalamic Disease.

Pathways for Hypothalamic Disease

Pathways related to Hypothalamic Disease according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 CRH GH1 GHRH POMC
2
Show member pathways
12.37 CRH GH1 GHRH GNRH1 POMC PRL
3
Show member pathways
12.25 GH1 GHRH GNRH1
4
Show member pathways
11.95 GH1 GHRH GNRH1
5
Show member pathways
11.79 GH1 GHRH GNRH1
6
Show member pathways
11.62 GH1 GHRH GNRH1
7 11.5 CRH GHRH POMC
8 11.49 CRH POMC
9 11.41 POMC PRL
10 11.19 GH1 GHRH GNRH1
11
Show member pathways
10.98 GH1 PRL
12 10.59 GH1 GHRH GNRH1
13 9.8 CRH POMC

GO Terms for Hypothalamic Disease

Cellular components related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 CRH GH1 GHRH GNRH1 POMC PRL
2 secretory granule GO:0030141 9.37 POMC PRL
3 perikaryon GO:0043204 9.33 CRH GHRH GNRH1
4 axon terminus GO:0043679 9.32 GHRH GNRH1
5 endosome lumen GO:0031904 9.26 GH1 PRL
6 extracellular space GO:0005615 9.1 CRH GH1 GHRH GNRH1 POMC PRL

Biological processes related to Hypothalamic Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.81 CRH GHRH GNRH1 POMC
2 positive regulation of cell proliferation GO:0008284 9.71 CRH GHRH PRL
3 cell-cell signaling GO:0007267 9.63 GHRH GNRH1 POMC
4 response to nutrient levels GO:0031667 9.52 GH1 PRL
5 positive regulation of multicellular organism growth GO:0040018 9.49 GH1 GHRH
6 positive regulation of JAK-STAT cascade GO:0046427 9.48 GH1 PRL
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.43 GH1 PRL
8 response to ethanol GO:0045471 9.43 CRH GNRH1 PRL
9 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.4 GH1 GHRH
10 parturition GO:0007567 9.37 CRH PRL
11 female pregnancy GO:0007565 9.33 CRH GNRH1 PRL
12 ovulation cycle GO:0042698 9.32 GNRH1 PRL
13 regulation of signaling receptor activity GO:0010469 9.02 GH1 GHRH GNRH1 POMC PRL
14 positive regulation of lactation GO:1903489 8.96 GHRH PRL

Molecular functions related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 CRH GHRH
2 hormone activity GO:0005179 9.1 CRH GH1 GHRH GNRH1 POMC PRL
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypothalamic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....